Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
Tarantino P, Burstein H, Lin N, Krop I, Winer E, Schnitt S, Hamilton E, Hurvitz S, Rugo H, Curigliano G, Tolaney S. Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? Annals Of Oncology 2021, 33: 234-238. PMID: 34942341, DOI: 10.1016/j.annonc.2021.12.004.Peer-Reviewed Original ResearchPhase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations
Xu J, Keenan TE, Overmoyer B, Tung NM, Gelman RS, Habin K, Garber JE, Ellisen LW, Winer EP, Goss PE, Yeap BY, Chabner BA, Isakoff SJ. Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. Breast Cancer Research And Treatment 2021, 189: 641-651. PMID: 34417675, DOI: 10.1007/s10549-021-06292-7.Peer-Reviewed Original ResearchConceptsObjective response rateClinical benefit rateProgression-free survivalMedian progression-free survivalMetastatic breast cancer patientsPhase II trialMetastatic breast cancerBreast cancer patientsBRCA1/2 carriersBreast cancerExpansion cohortII trialPrimary endpointPrimary cohortCancer patientsBenefit rateBRCA1/2 mutationsDay 1Longer median progression-free survivalSingle-arm phase II trialCommon grade 3Doses of veliparibPlatinum-naïve patientsPrior platinum therapyBRCA mutation carriers